APL
MCID: ACT119
MIFTS: 59

Acute Promyelocytic Leukemia (APL)

Categories: Blood diseases, Bone diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Acute Promyelocytic Leukemia

MalaCards integrated aliases for Acute Promyelocytic Leukemia:

Name: Acute Promyelocytic Leukemia 58 12 77 54 26 60 30 6 15 17 74
Acute Myeloblastic Leukemia Type 3 12 77 54
Leukemia, Acute Promyelocytic 58 26 13
Aml M3 54 26 60
Acute Myeloid Leukemia with T(15;17)(q22;q12);(pml/raralpha) and Variants 54 60
Aml with T(15;17)(q22;q12);(pml/raralpha) and Variants 54 60
Leukemia, Acute Promyelocytic, Somatic 58 41
Acute Myeloblastic Leukemia 3 54 60
Apml 54 60
Apl 58 26
Leukemia, Promyelocytic, Acute 45
Leukemia, Acute, Promyelocytic 41
Leukemia Promyelocytic Acute 56
Myeloid Leukemia, Acute, M3 26
Acute Myeloid Leukemia M3 12
M3 Anll 26

Characteristics:

Orphanet epidemiological data:

60
acute promyelocytic leukemia
Prevalence: 1-9/1000000 (United States),1-9/1000000 (Europe),1-9/1000000 (France); Age of onset: Adult; Age of death: elderly;

HPO:

33
acute promyelocytic leukemia:
Inheritance somatic mutation


Classifications:



External Ids:

Disease Ontology 12 DOID:0060318
OMIM 58 612376
MeSH 45 D015473
NCIt 51 C3182
SNOMED-CT 69 28950004
ICD10 34 C92.4 C92.40
MESH via Orphanet 46 D015473
ICD10 via Orphanet 35 C92.4
UMLS via Orphanet 75 C0023487
Orphanet 60 ORPHA520
MedGen 43 C0023487
SNOMED-CT via HPO 70 110004001 124975008 416627004
UMLS 74 C0023487

Summaries for Acute Promyelocytic Leukemia

NIH Rare Diseases : 54 Acute promyelocytic leukemia (APL) is an aggressive type of acute myeloid leukemia in which there are too many immature blood-forming cells (promyelocytes) in the blood and bone marrow. This build up of promyelocytes leads to a shortage of normal white and red blood cells and platelets in the body. The signs and symptoms of APL include an increased risk to both bleed and form blood clots. Individuals may also experience excessive tiredness, pain in affected areas, loss of appetite, and weight loss. APL usually occurs in middle-aged adults, but can be diagnosed at any age. It is caused by a mutation that is acquired over a person's lifetime, usually involving a translocation between chromosomes 15 and 17. Treatment may include the use of all-trans retinoic acid (ATRA) and arsenic trioxide or anthracycline-based chemotherapy.

MalaCards based summary : Acute Promyelocytic Leukemia, also known as acute myeloblastic leukemia type 3, is related to leukemia and leukemia, acute myeloid. An important gene associated with Acute Promyelocytic Leukemia is NUMA1 (Nuclear Mitotic Apparatus Protein 1), and among its related pathways/superpathways are MicroRNAs in cancer and miRNAs involved in DNA damage response. The drugs Adcetris and Sclerosol Intrapleural Aerosol have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are abnormal granulocytopoietic cell morphology and acute promyelocytic leukemia

Disease Ontology : 12 An acute myeloid leukemia characterized by accumulation of promyelocytes in the bone marrow and by a translocation between chromosomes 15 and 17.

Genetics Home Reference : 26 Acute promyelocytic leukemia is a form of acute myeloid leukemia, a cancer of the blood-forming tissue (bone marrow). In normal bone marrow, hematopoietic stem cells produce red blood cells (erythrocytes) that carry oxygen, white blood cells (leukocytes) that protect the body from infection, and platelets (thrombocytes) that are involved in blood clotting. In acute promyelocytic leukemia, immature white blood cells called promyelocytes accumulate in the bone marrow. The overgrowth of promyelocytes leads to a shortage of normal white and red blood cells and platelets in the body, which causes many of the signs and symptoms of the condition.

OMIM : 58 Acute promyelocytic leukemia (APL) is associated with 2 cardinal features: a granulocytic differentiation block and reciprocal and balanced translocations that always involve rearrangement of the RARA gene (180240). The most frequent translocation is t(15,17)(q21;q22), which fuses the RARA gene with the PML gene (102578) and represents more than 98% of APL (Vitoux et al., 2007). (612376)

Wikipedia : 77 Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid... more...

Related Diseases for Acute Promyelocytic Leukemia

Diseases related to Acute Promyelocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 234)
# Related Disease Score Top Affiliating Genes
1 leukemia 33.3 NEAT1 NPM1 PML RARA ZBTB16
2 leukemia, acute myeloid 31.3 MIR126 MIR210 MIR223 MIRLET7C NPM1 PML
3 leukemia, chronic lymphocytic 2 30.7 MIR15A MIR16-1 NEAT1
4 leukemia, acute lymphoblastic 30.3 MIR210 MIR223 MIRLET7C
5 thyroid cancer, nonmedullary, 1 30.3 MIR15A NEAT1 PVT1
6 aleukemic leukemia cutis 30.2 NPM1 RARA
7 glioma 30.0 MIR15A MIR210 NEAT1 PVT1
8 prostate cancer 29.4 MIR126 MIR15A MIR16-1 MIR210 MIR223 MIRLET7C
9 lung cancer 29.3 MIR126 MIR15A MIR210 MIRLET7A3 MIRLET7C MIRLET7D
10 hepatocellular carcinoma 29.3 MIR126 MIR15A MIR223 MIRLET7A3 MIRLET7C MIRLET7D
11 antiphospholipid syndrome 11.5
12 atrichia with papular lesions 11.4
13 sneddon syndrome 11.3
14 lipodystrophy, partial, acquired 11.3
15 myeloid leukemia 10.8
16 disseminated intravascular coagulation 10.6
17 thrombosis 10.6
18 hematologic cancer 10.5 NPM1 PVT1 RARA STAT5B
19 lymphoma 10.5
20 myelodysplastic syndrome 10.5
21 sarcoma 10.5
22 myeloid sarcoma 10.4
23 intracranial hypertension, idiopathic 10.4
24 acute leukemia 10.4
25 hematopoietic stem cell transplantation 10.4
26 multiple sclerosis 10.4
27 down syndrome 10.3
28 chromosomal triplication 10.3
29 lymphocytic leukemia 10.3
30 breast cancer 10.3
31 bone marrow necrosis 10.3
32 langerhans cell histiocytosis 10.2
33 leukemia, chronic myeloid 10.2
34 aplastic anemia 10.2
35 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.2
36 histiocytosis 10.2
37 pancreatitis 10.2
38 xp22.3 microdeletion syndrome 10.2
39 systemic lupus erythematosus 10.2
40 lupus erythematosus 10.2
41 leukemia, chronic lymphocytic 10.2
42 myelofibrosis 10.2
43 body mass index quantitative trait locus 1 10.2
44 myocardial infarction 10.2
45 myeloproliferative neoplasm 10.2
46 leukemia, b-cell, chronic 10.2
47 kidney cancer 10.2 MIR126 MIR15A MIR210 PVT1
48 pituitary adenoma 10.2 MIR15A MIR16-1 MIR223
49 hypertriglyceridemia, familial 10.1
50 myositis 10.1

Graphical network of the top 20 diseases related to Acute Promyelocytic Leukemia:



Diseases related to Acute Promyelocytic Leukemia

Symptoms & Phenotypes for Acute Promyelocytic Leukemia

Human phenotypes related to Acute Promyelocytic Leukemia:

33
# Description HPO Frequency HPO Source Accession
1 abnormal granulocytopoietic cell morphology 33 HP:0012135
2 acute promyelocytic leukemia 33 HP:0004836

Clinical features from OMIM:

612376

Drugs & Therapeutics for Acute Promyelocytic Leukemia

FDA approved drugs:

(show all 10)
# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Adcetris 19 50 BRENTUXIMAB VEDOTIN Seattle Genetics August 2011
2
Sclerosol Intrapleural Aerosol 19 50 TALC Bryan Corporation January 1998
3
Synercid I.V. 19 DALFOPRISTIN; QUINUPRISTIN QUINUPRISTIN; DALFOPRISTIN Rhone Poulenc Rorer September 1999
4
Temodar 19 50 TEMOZOLOMIDE Schering-Plough August 1999
5
Trisenox 19 50 ARSENIC TRIOXIDE Cell Therapeutics September 2000
6
Velcade 19 50 BORTEZOMIB Millennium Pharmaceuticals May 2003
7
Xalkori 19 50 CRIZOTINIB Pfizer August of 2011
8
Xtandi 19 50 ENZALUTAMIDE Medivation August 2012
9
Zykadia 19 50 CERITINIB Novartis April 2014
10
Alecensa 19 ALECTINIB HYDROCHLORIDE Roche December 2015

Drugs for Acute Promyelocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 207)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Arsenic trioxide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1327-53-3 518740
2
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Not Applicable 20830-81-3 30323
3
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58957-92-9 42890
4
Cytarabine Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 147-94-4, 65-46-3 6253
5
Mitoxantrone Approved, Investigational Phase 4,Phase 3 65271-80-9 4212
6
Mercaptopurine Approved Phase 4,Phase 3,Phase 2 50-44-2 667490
7
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
8
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
9
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
10
Thiotepa Approved, Investigational Phase 4,Phase 1 52-24-4 5453
11
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3 1177-87-3
12
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3 50-02-2 5743
13
Tretinoin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-79-4 444795 5538
14 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
15 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
16 Dermatologic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
17 Keratolytic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
18 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
19 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
20 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Analgesics Phase 4,Phase 3
25 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1
29 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
31 Antilymphocyte Serum Phase 4,Phase 2
32 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
33 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
34 glucocorticoids Phase 4,Phase 3,Phase 2
35 Antiemetics Phase 4,Phase 3,Phase 2
36 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
37 Hormones Phase 4,Phase 3,Phase 2
38 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
39 Hormone Antagonists Phase 4,Phase 3,Phase 2
40 Autonomic Agents Phase 4,Phase 3,Phase 2
41 BB 1101 Phase 4,Phase 3
42
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1 55-98-1 2478
43
leucovorin Approved Phase 3,Phase 2,Phase 1 58-05-9 143 6006
44
Thioguanine Approved Phase 3 154-42-7 2723601
45
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
46
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
47
Sargramostim Approved, Investigational Phase 3,Phase 2,Not Applicable 123774-72-1, 83869-56-1
48
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
49
Fludarabine Approved Phase 3,Phase 2,Phase 1 75607-67-9, 21679-14-1 30751
50
Methylprednisolone hemisuccinate Approved Phase 3,Phase 2 2921-57-5

Interventional clinical trials:

(show top 50) (show all 163)
# Name Status NCT ID Phase Drugs
1 Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic Unknown status NCT00196768 Phase 4 Arsenic trioxide;Trisenox
2 Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL Unknown status NCT01987297 Phase 4 ATRA+arsenic;ATRA+chemo
3 AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia Unknown status NCT00180128 Phase 4 all-trans retinoid acid;idarubicin;mitoxantrone;daunorubicin;cytarabine
4 Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA) Completed NCT00465933 Phase 4 AIDA
5 Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005) Completed NCT00408278 Phase 4 ATRA;Idarubicina;Mitoxantrone;ARA-C
6 Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) Completed NCT00504764 Phase 4 Arsenic Trioxide;ATRA
7 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
8 A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia Recruiting NCT02200978 Phase 4 ATO;RIF;ATRA;mitoxantrone;Ara-C;MTX;6MP
9 Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia Unknown status NCT00517712 Phase 2, Phase 3 Single agent arsenic trioxide
10 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia Unknown status NCT00002701 Phase 3 busulfan;cyclophosphamide;cytarabine;etoposide;idarubicin;mercaptopurine;methotrexate;mitoxantrone hydrochloride;thioguanine;tretinoin
11 Acute Promyelocytic Leukemia 2006 (APL) Unknown status NCT00378365 Phase 3
12 Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia Unknown status NCT01226303 Phase 3 ATRA;ATRA + IDA
13 Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients Unknown status NCT01633099 Phase 3 Decitabine
14 Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission Unknown status NCT00454168 Phase 3
15 Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
16 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia Completed NCT00866918 Phase 3 arsenic trioxide;mitoxantrone hydrochloride;idarubicin;tretinoin;cytarabine;mercaptopurine tablet;methotrexate
17 S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia Completed NCT00492856 Phase 3 mercaptopurine;methotrexate;tretinoin
18 Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia Completed NCT00003934 Phase 3 tretinoin;daunorubicin hydrochloride;cytarabine;mercaptopurine;methotrexate;arsenic trioxide
19 Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission Completed NCT00962767 Phase 3 gemtuzumab ozogamicin;ATRA plus 6-MP and MTX
20 A Randomized Trial Assessing the Roles of AraC in Newly Diagnosed APL Promyelocytic Leukemia (APL) Completed NCT00591526 Phase 3 Arac
21 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia Completed NCT00003436 Phase 3 amsacrine;asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;methotrexate;mitoxantrone hydrochloride;therapeutic hydrocortisone
22 flt3L in Treating Patients With Acute Myeloid Leukemia Completed NCT00006223 Phase 3
23 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
24 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
25 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
26 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
27 Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia Recruiting NCT02339740 Phase 3 Arsenic Trioxide;Cytarabine;Dexamethasone;Idarubicin;Mitoxantrone Hydrochloride;Tretinoin
28 Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia Recruiting NCT02688140 Phase 3 Arsenic trioxide;Idarubicin;Cytarabine;Tretinoin;Mitoxantrone;Mercaptopurine;Methotrexate
29 Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF) Recruiting NCT02899169 Phase 3 Realgar-Indigo naturalis formula;all-trans retinoic acid;Arsenic trioxide;Hydroxyurea
30 A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old Recruiting NCT03257241 Phase 3 A arm (DA-90);B arm (DAC);A arm (CLAG-M);B arm (FLAG-IDA)
31 An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia Recruiting NCT03151408 Phase 3 Pracinostat;Placebos;Azacitidine
32 Phase III Trial in Acute Promyelocytic Leukemia Patients Active, not recruiting NCT00482833 Phase 3 arsenic trioxide;idarubicin;mercaptopurine;methotrexate;all-trans retinoic acid;all-trans retinoic acid (ATRA)
33 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
34 Proteasome Inhibition in Acute Promyelocytic Leukemia Unknown status NCT01950611 Phase 2 Bortezomib
35 Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia Unknown status NCT00675870 Phase 2 NRX 195183 Soft Gelatin Capsule
36 FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML Unknown status NCT00559221 Phase 2 FLAG+IDA
37 Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML Unknown status NCT00529880 Phase 2 Fludarabine , cytarabine
38 Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible Unknown status NCT02261779 Phase 1, Phase 2 Tranylcypromine;Tretinoin
39 Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation Unknown status NCT00036712 Phase 2
40 Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia Completed NCT00008697 Phase 1, Phase 2 arsenic trioxide
41 Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission Completed NCT00002609 Phase 2 cytarabine;idarubicin
42 Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia Completed NCT00276601 Phase 2 arsenic trioxide;cytarabine;daunorubicin hydrochloride;mercaptopurine;methotrexate;tretinoin
43 All-trans Retinoic Acid, and Arsenic +/- Idarubicin Completed NCT00413166 Phase 2 All-Trans Retinoic Acid (ATRA);Arsenic Trioxide (ATO);Idarubicin;Gemtuzumab Ozogamicin
44 S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia Completed NCT00551460 Phase 2 arsenic trioxide;gemtuzumab ozogamicin;mercaptopurine;methotrexate;tretinoin
45 Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia Completed NCT00016159 Phase 2 arsenic trioxide;idarubicin;tretinoin
46 Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL Completed NCT00520208 Phase 2 Tamibarotene
47 Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector Completed NCT01428128 Phase 2 Arsenic Trioxide
48 Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible Completed NCT01361334 Phase 2 Pazopanib
49 Study of Arsenic Trioxide in Small Cell Lung Cancer Completed NCT01470248 Phase 2 Arsenic Trioxide
50 Selinexor (KPT-330) in Older Patients With Relapsed AML Completed NCT02088541 Phase 2 Selinexor;Hydroxyurea;Ara-C;Azacitidine;Decitabine

Search NIH Clinical Center for Acute Promyelocytic Leukemia

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: leukemia, promyelocytic, acute

Genetic Tests for Acute Promyelocytic Leukemia

Genetic tests related to Acute Promyelocytic Leukemia:

# Genetic test Affiliating Genes
1 Acute Promyelocytic Leukemia 30 NUMA1 RARA

Anatomical Context for Acute Promyelocytic Leukemia

MalaCards organs/tissues related to Acute Promyelocytic Leukemia:

42
Myeloid, Bone, Bone Marrow, Lung, Brain, Skin, Prostate

Publications for Acute Promyelocytic Leukemia

Articles related to Acute Promyelocytic Leukemia:

(show top 50) (show all 3034)
# Title Authors Year
1
New onset acute promyelocytic Leukemia during pregnancy: report of 2 cases. ( 30453810 )
2019
2
Real-life Outcomes on Acute Promyelocytic Leukemia in Brazil - Early Deaths Are Still a Problem. ( 30509780 )
2019
3
Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy. ( 30526152 )
2019
4
Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid. ( 30526180 )
2019
5
Droplet digital PCR for quantification of PML-RARα in acute promyelocytic leukemia: a comprehensive comparison with real-time PCR. ( 30617397 )
2019
6
RARγ-rearrangements resemble acute promyelocytic leukemia and benefit from 3 + 7 regimen. ( 30632861 )
2019
7
Diethyl [(3-phenoxy-2-oxo-4-phenyl-azetidin-1-yl)-phenyl-methyl]-phosphonate as a potent anticancer agent in chemo-differentiation therapy of acute promyelocytic leukemia. ( 30639798 )
2019
8
Proteomic Profiling of Acute Promyelocytic Leukemia Identifies Two Protein Signatures Associated with Relapse. ( 30650251 )
2019
9
Early and sensitive detection of PML-A216V mutation by droplet digital PCR in ATO-resistant acute promyelocytic leukemia. ( 30651632 )
2019
10
Contributory role of microRNAs in anti-cancer effects of small molecule inhibitor of telomerase (BIBR1532) on acute promyelocytic leukemia cell line. ( 30658112 )
2019
11
Factors Affecting Early Death and Survival of Patients With Acute Promyelocytic Leukemia Treated With ATRA-Based Therapy Regimens. ( 30661514 )
2019
12
Flexural Eruption Associated With Arsenic Trioxide Therapy in a Patient With Acute Promyelocytic Leukemia. ( 30673070 )
2019
13
A complex translocation (1;17;15) with spliced short-type PML-RARA fusion transcripts in acute promyelocytic leukemia: A case report. ( 30680014 )
2019
14
Comparing the epidemiology, clinical characteristics and prognostic factors of acute myeloid leukemia with and without acute promyelocytic leukemia. ( 30715157 )
2019
15
Serendipity: decitabine monotherapy induced complete molecular response in a 77-year-old patient with acute promyelocytic leukemia. ( 30733274 )
2019
16
Toward Candidate Proteomic Biomarkers in Clinical Monitoring of Acute Promyelocytic Leukemia Treatment with Arsenic Trioxide. ( 30767729 )
2019
17
Strategies to inhibit arsenic trioxide-induced cardiotoxicity in acute promyelocytic leukemia. ( 30770558 )
2019
18
Time course of arsenic species in red blood cells of acute promyelocytic leukemia (APL) patients treated with single agent arsenic trioxide. ( 30795697 )
2019
19
Influence of bcr-3 PML-RARα transcript on outcome in Acute Promyelocytic Leukemia patients of Kashmir treated with all-trans retinoic acid and/or arsenic tri-oxide. ( 30803552 )
2019
20
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. ( 30803991 )
2019
21
Myeloid neoplasm with eosinophilia and PCM1-JAK2 associated with acute promyelocytic leukemia with PML-RARA. ( 30806106 )
2019
22
Autophagy is Required to Regulate Mitochondria Renewal, Cell Attachment, and All-trans-Retinoic Acid-Induced Differentiation in NB4 Acute Promyelocytic Leukemia Cells. ( 30806286 )
2019
23
Successful Treatment With ATRA and Arsenic Trioxide for a Child With Down Syndrome and Acute Promyelocytic Leukemia. ( 30807394 )
2019
24
Fatal Intracranial Hemorrhage in a Young Pregnant Patient with Acute Promyelocytic Leukemia. ( 30814083 )
2019
25
A novel flow cytometric method for enhancing acute promyelocytic leukemia screening by multidimensional dot-plots. ( 30830246 )
2019
26
The combination of UCN-01 and ATRA triggers differentiation in ATRA resistant acute promyelocytic leukemia cell lines via RAF-1 independent activation of MEK/ERK. ( 30840849 )
2019
27
Acute promyelocytic leukemia presenting as recurrent spinal myeloid sarcomas 3 years before developing leukemia: A case report with review of literature. ( 30847197 )
2019
28
Predictors of early hemorrhage in acute promyelocytic leukemia. ( 30849255 )
2019
29
Fournier's gangrene as an initial manifestation of acute promyelocytic leukemia: A case report and review of the literature. ( 30854206 )
2019
30
Phenylarsine Oxide can Induce Degradation of PLZF-RARα Variant Fusion Protein of APL. ( 30869512 )
2019
31
Addressing the Room for Improvement in Management of Acute Promyelocytic Leukemia. ( 30887583 )
2019
32
Non-acute promyelocytic leukemia variant, acute myeloid leukemia with translocation (11;17). ( 30899494 )
2019
33
Corpus Callosum Bleed: A Rare Presentation of Acute Promyelocytic Leukemia. ( 30988588 )
2019
34
RNF8 is responsible for ATRA resistance in variant acute promyelocytic leukemia with GTF2I/RARA fusion, and inhibition of the ubiquitin-proteasome pathway contributes to the reversion of ATRA resistance. ( 30992691 )
2019
35
Multidimensional radar dot-plots, do we need it for the screening of acute promyelocytic leukemia? ( 31025159 )
2019
36
MLL-rearrangement can resemble acute promyelocytic leukemia. ( 31038019 )
2019
37
Automated detection of acute promyelocytic leukemia using an ADVIA 2120i. ( 31050878 )
2019
38
Real life outcomes of patients aged ≥75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry. ( 31068052 )
2019
39
Effect of combination of all-trans retinoic acid and arsenic trioxide on apoptosis of acute promyelocytic leukemia cells. ( 31078158 )
2019
40
Oral arsenic trioxide incorporation into frontline treatment with all-trans retinoic acid and chemotherapy in newly diagnosed acute promyelocytic leukemia: A 5-year prospective study. ( 31090936 )
2019
41
Pathogenetic implication of fusion genes in acute promyelocytic leukemia and their diagnostic utility. ( 29700805 )
2019
42
RACK1 deficiency synergizes with all-trans retinoic acid to induce apoptosis in human acute promyelocytic leukemia cells. ( 30019299 )
2019
43
Cytogenetically cryptic insertion of PML segment into RARA on chromosome 17q resulting PML-RARA fusion in acute promyelocytic leukemia. ( 30030569 )
2019
44
2-Bromopalmitate targets retinoic acid receptor alpha and overcomes all-trans retinoic acid resistance of acute promyelocytic leukemia. ( 30076181 )
2019
45
Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukemia: a final result of prospective, randomized, JALSG-APL204 study. ( 30093681 )
2019
46
Risk Markers for Significant Bleeding and Thrombosis in Pediatric Acute Promyelocytic Leukemia; Report From the Children's Oncology Group Study AAML0631. ( 30095694 )
2019
47
Transglutaminase 2 programs differentiating acute promyelocytic leukemia cells in all-trans retinoic acid treatment to inflammatory stage through NF-κB activation. ( 30237268 )
2019
48
Clinical and molecular features of acute promyelocytic leukemia with variant retinoid acid receptor fusions. ( 30237272 )
2019
49
Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance). ( 30393935 )
2019
50
Identification and monitoring of atypical PML/RARA fusion transcripts in acute promyelocytic leukemia. ( 30421475 )
2019

Variations for Acute Promyelocytic Leukemia

ClinVar genetic disease variations for Acute Promyelocytic Leukemia:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 TMEM127 NM_017849.3(TMEM127): c.31G> T (p.Gly11Cys) single nucleotide variant Uncertain significance GRCh38 Chromosome 2, 96265351: 96265351
2 TMEM127 NM_017849.3(TMEM127): c.31G> T (p.Gly11Cys) single nucleotide variant Uncertain significance GRCh37 Chromosome 2, 96931089: 96931089

Copy number variations for Acute Promyelocytic Leukemia from CNVD:

7 (show all 28)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 17351 1 142487224 245120412 Gain Acute promyelocytic leukemia
2 29128 1 227843862 227867765 Deletion EGLN1 Acute promyelocytic leukemia
3 44777 10 62496958 68046104 Deletion Acute promyelocytic leukemia
4 71119 12 6755671 29248257 Deletion Acute promyelocytic leukemia
5 78273 13 49630676 50510777 Deletion DLEU7 Acute promyelocytic leukemia
6 78274 13 49630676 50510777 Deletion FAM10A4 Acute promyelocytic leukemia
7 78275 13 49630676 50510777 Deletion GUCY1B2 Acute promyelocytic leukemia
8 78767 13 56784440 114051465 Duplication Acute promyelocytic leukemia
9 93669 15 57244668 100182183 Duplication Acute promyelocytic leukemia
10 94970 15 72224840 100192115 Duplication Acute promyelocytic leukemia
11 108134 17 18901 21459693 Deletion Acute promyelocytic leukemia
12 108602 17 21491135 35542587 Duplication Acute promyelocytic leukemia
13 123386 18 7192739 7657575 Duplication PTPRM Acute promyelocytic leukemia
14 157044 21 1 48129895 Tri Acute promyelocytic leukemia
15 158722 21 36234195 46924583 Duplication Acute promyelocytic leukemia
16 181722 4 125190507 126521903 Deletion Acute promyelocytic leukemia
17 214094 6 5545437 8054930 Deletion Acute promyelocytic leukemia
18 220370 7 137795618 137920872 Translate TIF1 Acute promyelocytic leukemia
19 226739 7 61522282 158554645 Deletion Acute promyelocytic leukemia
20 228938 7 85414972 86445002 Deletion DMTF1 Acute promyelocytic leukemia
21 228939 7 85414972 86445002 Deletion GRM3 Acute promyelocytic leukemia
22 228940 7 85414972 86445002 Deletion KIAA1324L Acute promyelocytic leukemia
23 230737 8 1 146364022 Tri Acute promyelocytic leukemia
24 233093 8 122607785 132092760 Duplication Acute promyelocytic leukemia
25 254363 9 64207745 111479523 Deletion Acute promyelocytic leukemia
26 256567 9 94435025 94710006 Duplication C9orf3 Acute promyelocytic leukemia
27 256568 9 94435025 94710006 Duplication FBP1 Acute promyelocytic leukemia
28 256569 9 94435025 94710006 Duplication FBP2 Acute promyelocytic leukemia

Expression for Acute Promyelocytic Leukemia

Search GEO for disease gene expression data for Acute Promyelocytic Leukemia.

Pathways for Acute Promyelocytic Leukemia

Pathways related to Acute Promyelocytic Leukemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.7 MIR126 MIR15A MIR16-1 MIR210 MIR223 MIRLET7A3
2 11.13 MIR16-1 MIR210 MIRLET7D
3 10.78 MIRLET7A3 MIRLET7C MIRLET7D
4 10.51 PML RARA ZBTB16

GO Terms for Acute Promyelocytic Leukemia

Cellular components related to Acute Promyelocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 MIR126 MIR15A MIR16-1 MIR210 MIR223 MIRLET7A3
2 micro-ribonucleoprotein complex GO:0035068 9.28 MIR126 MIR15A MIR16-1 MIR210 MIR223 MIRLET7A3
3 spindle pole centrosome GO:0031616 9.16 NPM1 NUMA1

Biological processes related to Acute Promyelocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.91 MIRLET7C NPM1 RARA STAT5B TBL1XR1 ZBTB16
2 negative regulation of cell proliferation GO:0008285 9.63 MIR15A MIR16-1 NPM1 PML RARA ZBTB16
3 negative regulation of angiogenesis GO:0016525 9.54 MIR15A MIR16-1 PML
4 negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903588 9.48 MIR15A MIR16-1
5 myeloid cell differentiation GO:0030099 9.46 PML ZBTB16
6 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.4 MIR15A MIR223
7 retinoic acid receptor signaling pathway GO:0048384 9.32 PML RARA
8 gene silencing by miRNA GO:0035195 9.28 MIR126 MIR15A MIR16-1 MIR210 MIR223 MIRLET7A3
9 negative regulation of cell chemotaxis to fibroblast growth factor GO:1904848 9.26 MIR15A MIR16-1
10 miRNA mediated inhibition of translation GO:0035278 9.26 MIR15A MIR16-1 MIR210 MIRLET7A3

Molecular functions related to Acute Promyelocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein domain specific binding GO:0019904 9.26 NUMA1 PRKAR1A RARA ZBTB16
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.1 MIR126 MIR15A MIR16-1 MIR210 MIR223 MIRLET7C

Sources for Acute Promyelocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....